VACCINE FOR SHIGELLA
    5.
    发明申请
    VACCINE FOR SHIGELLA 失效
    疫苗用于SHIGELLA

    公开(公告)号:US20110212125A1

    公开(公告)日:2011-09-01

    申请号:US13059051

    申请日:2009-08-14

    摘要: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr—Sr—O—N═C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: α-L-AltNAcA-3-β-FucNAc4N-4-.

    摘要翻译: 公开了包括这种免疫原性缀合物的免疫原性缀合物和治疗组合物。 还公开了治疗和/或抑制志贺氏杆菌感染的方法。 所公开的免疫原性缀合物具有以下通用结构:Pr-Sr-O-N = C-Kdo-OS,其中Pr是载体蛋白,Sr是任选的间隔基部分,Kdo是3-脱氧-D-丙氨酸辛酯酸或 其衍生物,OS是从S. sonnei获得的寡糖或多糖。 在具体实例中,免疫原性缀合物包括从具有以下结构的S. sonnei获得的核心寡糖:其中R为1至10个二糖重复单元。 在具体实例中,包含在免疫原性缀合物中的二糖重复单元具有以下结构:α-L-AltNAcA-3-&bgr-FucNAc4N-4-。

    METHODS FOR PREPARING IMMUNOGENIC CONJUGATES
    6.
    发明申请
    METHODS FOR PREPARING IMMUNOGENIC CONJUGATES 有权
    制备免疫原性结合蛋白的方法

    公开(公告)号:US20100040644A1

    公开(公告)日:2010-02-18

    申请号:US12582420

    申请日:2009-10-20

    摘要: Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage.

    摘要翻译: 制备免疫原性缀合物的方法,其包括与载体共价连接的半抗原或抗原。 所述方法包括使第一试剂与二酰肼反应,得到肼修饰的第一试剂,其中第一试剂是半抗原,抗原或载体; 使第二试剂与苯甲醛化合物反应,得到苯甲醛修饰的第二试剂,其中第二试剂是半抗原,抗原或载体,条件是第一试剂或第二试剂是载体; 并使肼修饰的第一试剂与苯甲醛修饰的第二试剂反应,得到包含通过腙键与载体共价连接的半抗原或抗原的免疫原性缀合物。

    VACCINES AGAINST INFLUENZA VIRUS
    7.
    发明申请
    VACCINES AGAINST INFLUENZA VIRUS 失效
    疫苗对流感病毒

    公开(公告)号:US20100150954A1

    公开(公告)日:2010-06-17

    申请号:US12541804

    申请日:2009-08-14

    摘要: Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.

    摘要翻译: 公开了具有以下通式的免疫原性缀合物:M2e-Cys-S-CH2-C(O)-NH-CH2-CH2-C(O-NH-Lys-Pr),M2e是流感M2胞外域(M2e)肽 ; Cys是存在于M2e肽中的半胱氨酸氨基酸残基; S存在于半胱氨酸氨基酸残基中的硫; CH2-CO-NH-CH2-CH2-CO连接基团; NH存在于载体的赖氨酸残基中的胺基; Lys是赖氨酸氨基酸残基,Pr是载体蛋白。 还公开了分离的免疫原,其包括包括多碱性切割位点的流感HA蛋白的免疫原性片段,其中已经修饰了流感HA蛋白的免疫原性片段以除去N-末端前导氨基酸序列和C-末端跨膜结构域 。 还公开了产生针对所鉴定的流感病毒株特异的流感疫苗的方法。

    Vaccine for shigella
    9.
    发明授权
    Vaccine for shigella 失效
    志贺氏菌疫苗

    公开(公告)号:US08747863B2

    公开(公告)日:2014-06-10

    申请号:US13059051

    申请日:2009-08-14

    摘要: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr—Sr—O—N═C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: α-L-AltNAcA-3-β-FucNAc4N-4-.

    摘要翻译: 公开了包括这种免疫原性缀合物的免疫原性缀合物和治疗组合物。 还公开了治疗和/或抑制志贺氏杆菌感染的方法。 所公开的免疫原性缀合物具有以下通用结构:Pr-Sr-O-N = C-Kdo-OS,其中Pr是载体蛋白,Sr是任选的间隔子部分,Kdo是3-脱氧-D-丙氨酸辛酯酸或 其衍生物,OS是从S. sonnei获得的寡糖或多糖。 在具体实例中,免疫原性缀合物包括从具有以下结构的S. sonnei获得的核心寡糖:其中R为1至10个二糖重复单元。 在具体实例中,包含在免疫原性缀合物中的二糖重复单元具有以下结构:α-L-AltNAcA-3-&bgr-FucNAc4N-4-。

    Vaccines against influenza virus
    10.
    发明授权
    Vaccines against influenza virus 失效
    针对流感病毒的疫苗

    公开(公告)号:US08658180B2

    公开(公告)日:2014-02-25

    申请号:US12541804

    申请日:2009-08-14

    摘要: Disclosed are immunogenic conjugates having the general formula: M2e-Cys-S—CH2—C(O)—NH—CH2—CH2-C(O—)NH-Lys-Pr, were M2e is the influenza M2 ectodomain (M2e) peptide; Cys is a cysteine amino acid residue present in the M2e peptide; S the sulfur present in the cysteine amino acid residue; CH2-CO—NH—CH2-CH2-CO the linking group; NH the amine group present in a lysine residue of the carrier; Lys is a lysine amino acid residue and Pr the carrier protein. Also disclosed are isolated immunogens that include an immunogenic fragment of an influenza HA protein including the polybasic cleavage site, wherein the immunogenic fragment of the influenza HA protein has been modified to remove an N-terminal leader amino acid sequence and a C-terminal transmembrane domain. Also disclosed are methods producing an influenza vaccine specific for an identified influenza strain.

    摘要翻译: 公开了具有以下通式的免疫原性缀合物:M2e-Cys-S-CH2-C(O)-NH-CH2-CH2-C(O-NH-Lys-Pr),M2e是流感M2胞外域(M2e)肽 ; Cys是存在于M2e肽中的半胱氨酸氨基酸残基; S存在于半胱氨酸氨基酸残基中的硫; CH2-CO-NH-CH2-CH2-CO连接基团; NH存在于载体的赖氨酸残基中的胺基; Lys是赖氨酸氨基酸残基,Pr是载体蛋白。 还公开了分离的免疫原,其包括包括多碱性切割位点的流感HA蛋白的免疫原性片段,其中已经修饰了流感HA蛋白的免疫原性片段以除去N-末端前导氨基酸序列和C-末端跨膜结构域 。 还公开了产生针对所鉴定的流感病毒株特异的流感疫苗的方法。